Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | CPN1 | P15169 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26977202 | 0.81 | CHRM1 (0.35) | GAACPN1CPB2L3MBTL1ALDH1A1 | |
| SCHEMBL7191030 | 0.81 | CYP1A2 (0.34) | GAACPN1CPB2L3MBTL1CYP1A2 | |
| SCHEMBL7879384 | 0.79 | CA2 (0.37) | GAACPN1CPB2L3MBTL1ALDH1A1 | |
| SCHEMBL756072 | 0.79 | FFAR4 (0.37) | TSHRALDH1A1ALOX15TDP1 | |
| SCHEMBL26977293 | 0.78 | GPR84 (0.39) | — | |
| SCHEMBL669633 | 0.77 | HTT (0.39) | GAACPN1CPB2CYP1A2TSHR | |
| SCHEMBL669634 | 0.77 | HTT (0.39) | GAACPN1CPB2CYP1A2TSHR | |
| SCHEMBL7509572 | 0.76 | GPR84 (0.41) | — | |
| SCHEMBL755538 | 0.76 | GPR84 (0.41) | — | |
| SCHEMBL26977190 | 0.76 | GPR84 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3310819-B1 | COMPOSITION FOR IMMEDIATELY ENDING RADICAL POLYMERIZATION | BASF SE (DE) | 2019-06-12 | — | — | EP | disclosed |
| US-10221255-B2 | Composition for the immediate stopping of a free-radical polymerization | BASF SE (DE) | 2019-03-05 | — | — | US | disclosed |
| US-20180171035-A1 | COMPOSITION FOR THE IMMEDIATE STOPPING OF A FREE-RADICAL POLYMERIZATION | BASF SE (DE) | 2018-06-21 | — | — | US | disclosed |
| US-20180171035-A1 | COMPOSITION FOR THE IMMEDIATE STOPPING OF A FREE-RADICAL POLYMERIZATION | BASF SE (DE) | 2018-06-21 | — | — | US | disclosed |
| WO-2016202883-A1 | COMPOSITION FOR IMMEDIATELY ENDING RADICAL POLYMERIZATION | BASF SE (DE) | 2016-12-22 | — | — | WO | disclosed |
| EP-1345882-A2 | METHOD FOR PRODUCING (METH)ACRYLIC ACID | BASF AKTIENGESELLSCHAFT (DE) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002051786-A2 | METHOD FOR PRODUCING (METH)ACRYLIC ACID | BASF AKTIENGESELLSCHAFT (DE) | 2002-07-04 | — | — | WO | disclosed |
| WO-2000069793-A1 | MIXTURE OF SUBSTANCES, COMPRISING STABILISERS AND COMPOUNDS WHICH CONTAIN VINYL GROUPS | BASF AKTIENGESELLSCHAFT (DE) | 2000-11-23 | — | — | WO | disclosed |
| EP-1034201-A1 | METHOD FOR PRODUCING GRAFT POLYMERS | BASF AKTIENGESELLSCHAFT (DE) | 2000-09-13 | — | — | EP | disclosed |
| EP-0941254-A1 | METHOD FOR POLYMERIZING VINYL MONOMERS | BASF AKTIENGESELLSCHAFT (DE) | 1999-09-15 | — | — | EP | disclosed |
| WO-1999025749-A1 | METHOD FOR PRODUCING GRAFT POLYMERS | BASF AKTIENGESELLSCHAFT (DE) | 1999-05-27 | — | — | WO | disclosed |
| WO-1998023649-A1 | METHOD FOR POLYMERIZING VINYL MONOMERS | BASF AKTIENGESELLSCHAFT (DE) | 1998-06-04 | — | — | WO | disclosed |
| EP-0815082-A1 | 4-ACYLAMINO PIPERIDIN-N-OXYLS | BASF AKTIENGESELLSCHAFT (DE) | 1998-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221255-B2 | Composition for the immediate stopping of a free-radical polymerization | FASTKD5, TYK2, FASTKD1 | GAA 4489/4885CPN1 1424/4885CPB2 1912/4885 |
| US-20180171035-A1 | COMPOSITION FOR THE IMMEDIATE STOPPING OF A FREE-RADICAL POLYMERIZATION | FASTKD5, TYK2, FASTKD1 | GAA 4489/4885CPN1 1424/4885CPB2 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.